Company Overview

C4 Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on targeted protein degradation, a therapeutic approach designed to eliminate disease-causing proteins rather than inhibit them. The company operates within the biotechnology and precision medicine industries, with a primary emphasis on oncology. Its proprietary platform is built around targeted protein degrader technologies, including bifunctional degrader molecules intended to harness the body’s natural ubiquitin-proteasome system to selectively degrade proteins associated with cancer and other diseases.

The company’s primary value drivers are its internally developed oncology pipeline, platform licensing arrangements, and strategic research collaborations with larger pharmaceutical companies. Key programs have focused on targets such as IKZF1/3, BRAF, and EGFR mutations associated with solid tumors and hematologic malignancies. Founded in 2015 and headquartered in Watertown, Massachusetts, C4 Therapeutics evolved from academic and scientific advances in targeted protein degradation developed by founders and researchers associated with the Dana-Farber Cancer Institute and related scientific institutions. The company completed its initial public offering in 2020 and has continued expanding its degrader platform through partnerships and internal R&D.

Business Operations

C4 Therapeutics primarily operates through a unified biotechnology business model centered on discovery, development, and commercialization of targeted protein degrader therapies. Its operations include preclinical research, clinical development, translational medicine, and strategic partnering activities. Revenue has historically been generated through collaboration agreements, upfront licensing payments, research funding, milestone payments, and to a lesser extent investment income, as the company remains in the clinical development stage and has not reported commercial product sales based on publicly available filings.

The company controls proprietary degrader discovery technologies, including its TORPEDO® platform, which is designed to identify and optimize degrader molecules against difficult-to-drug targets. C4 Therapeutics has established collaborations with pharmaceutical companies including Merck & Co., Roche, and Betta Pharmaceuticals, among others, focused on advancing degrader candidates across oncology indications. Operations are primarily U.S.-based, though clinical development activities and partnership relationships extend internationally through collaborative research and licensing arrangements.

Strategic Position & Investments

C4 Therapeutics’ strategic direction centers on expanding the therapeutic applications of targeted protein degradation and advancing wholly owned oncology assets through clinical development. The company has prioritized precision oncology programs directed at validated cancer drivers while also seeking to broaden the degrader modality into additional disease areas where selective protein elimination may provide advantages over traditional inhibition approaches. Public filings and investor materials indicate a continued emphasis on optimizing oral bioavailability, selectivity, and degradation efficiency within its platform technologies.

The company has invested substantially in research and development infrastructure, translational biology capabilities, and clinical-stage assets. Key strategic collaborations with larger pharmaceutical companies have provided non-dilutive funding and external validation of its degrader platform. Its portfolio includes internally developed programs as well as partnered discovery initiatives targeting historically difficult proteins. C4 Therapeutics also maintains intellectual property related to degrader chemistry and protein degradation mechanisms, which management has identified as a competitive differentiator within the emerging targeted protein degradation sector.

Geographic Footprint

C4 Therapeutics is headquartered in Watertown, Massachusetts, within the greater Boston biotechnology ecosystem. The company’s principal operations, research activities, and corporate functions are concentrated in the United States, though its development programs have international relevance through multinational collaborations and global oncology research networks.

Through partnerships and licensing arrangements, the company maintains operational and strategic connections across North America, Europe, and Asia-Pacific. Collaborations with multinational pharmaceutical companies and regional partners have expanded its access to international research capabilities, clinical development infrastructure, and potential commercialization channels. Public disclosures indicate that while the company does not maintain a broad global commercial footprint, its therapeutic programs are designed for worldwide oncology markets.

Leadership & Governance

C4 Therapeutics was founded by scientists and biotechnology leaders involved in advancing the field of targeted protein degradation, including researchers associated with pioneering ubiquitin-proteasome system research. The company is governed by a board and executive leadership team with experience across oncology drug development, biotechnology commercialization, and pharmaceutical partnerships. Management has consistently emphasized disciplined capital allocation, clinically differentiated degrader candidates, and strategic collaborations as core components of the company’s long-term strategy.

Key executives identified in recent public filings and company disclosures include:

• Andrew Hirsch – President and Chief Executive Officer
• Brandon Bentz – Chief Financial Officer
• Adam Crystal, M.D., Ph.D. – Chief Medical Officer
• Jingjing Wang, Ph.D. – Chief Scientific Officer
• Scott Boyle – Chief Business Officer

The company’s leadership philosophy, as reflected in investor communications and regulatory filings, emphasizes scientific rigor, translational precision medicine, and leveraging strategic partnerships to accelerate the development of targeted protein degrader therapies.